

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
May 28, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the “Company”), received a notice from the National Medical Products Administration (hereinafter referred to as “NMPA”) approving the Company’s self-developed Class 1 innovative drug Ruzinurad Tablets (SHR4640 tablets) for marketing. This product is China’s first self-developed new-generation URAT1 inhibitor with high selectivity. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Drug Name: Ruzinurad Tablets

Dosage Form: Tablets

Strength: 1 mg, 2.5 mg

Registered Category: Class 1 chemical drug

Acceptance No.: CXHS2500003, CXHS2500004

Prescription/Non-prescription Drug: Prescription Drug

Approved indications: This product is indicated for patients with gout and hyperuricemia.

II. Other Information of the Drug

The prevalence of hyperuricemia in Chinese adults is as high as 17.7%, affecting approximately 180 million people; the prevalence of gout is 3.2%, affecting

approximately 36 million people¹. The dynamic loss of balance of the “uric acid pool” caused by excessive uric acid production or insufficient uric acid excretion is the main pathological link leading to hyperuricemia². In turn, hyperuricemia is the most significant risk factor for the onset and progression of gout³.

Uric acid-lowering treatment is the core strategy for the long-term management of gout disease. Currently, the commonly used xanthine oxidase (XO) inhibitors in clinic (such as Febuxostat) act on the uric acid biosynthesis pathway, with the intended effect of reducing uric acid production; however, approximately 2/3 of the uric acid produced by the body needs to be excreted through the kidneys, and even if production is reduced, insufficient renal excretion will still hinder the achievement of target serum uric acid (sUA) levels². Studies have shown that 30% to 70% of patients treated with XO inhibitors alone still fail to achieve the target sUA level⁴.

Urate transporter 1 (URAT1) assumes approximately 90% of uric acid reabsorption function of kidney and is a core target for regulating uric acid excretion⁵. Ruzinurad tablets are a Class 1 novel small-molecule drug independently developed by the Company. It can highly selectively inhibit URAT1, suppress renal tubular reabsorption of uric acid and enhance uric acid excretion, thereby effectively reducing sUA levels. At present, there is a large population of gout patients in China, with an increasing number and a trend toward younger patients year by year. However, the therapeutic drugs still remain very limited⁶. The only marketed highly selective URAT1 inhibitor for gout accompanying hyperuricemia worldwide is the Dotinurad Tablet, which was approved in January 2020. This product was approved for marketing in China in December 2024. According to publicly available data, the global sales revenue of Dotinurad Tablets reached approximately USD 39.34 million in 2025. As of the date hereof, the cumulative research and development (R&D) investment in the Ruzinurad tablets project has amounted to approximately RMB 312.2 million (unaudited).

III. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors

are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

May 28, 2026

- [1] Song J, et al. J Transl Int Med. 2022;10(2):134-145.
- [2] Xu L, et al. Cell Commun Signal. 2025;23(1):4.
- [3] Chinese Society of Endocrinology, Chinese Medical Association. Chinese Journal of Endocrinology and Metabolism, 2025,41(10): 806-817.
- [4] Xie H, et al. BMC Pharmacol Toxicol. 2023 Dec 14;24(1):79.
- [5] Song D, et al. Eur J Pharmacol. 2021 Sep 15;907:174291.
- [6] Zhong Y, et al. Front Public Health. 2025 Jun 9;13:1613801.